Want to see PVLA full AI Analyst Report?
PVLA Stock Chart & Stats
$138.01
$3.76(2.72%)
At close: 4:00 PM EDT
$138.01
$3.76(2.72%)
Day’s Range― - ―
52-Week Range$41.71 - $161.38
Previous Close$141.77
Volume173.59K
Average Volume (3M)290.36K
Market Cap
$2.23B
Enterprise Value$1.97K
Total Cash (Recent Filing)$250.58M
Total Debt (Recent Filing)$535.00K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 17, 2026EPS Estimate
-1.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.83
Shares Outstanding14,408,407
10 Day Avg. Volume255,683
30 Day Avg. Volume290,357
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)42.09
Price to Sales (P/S)0.00
P/FCF Ratio-47.10
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$233.82Price Target Upside69.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Compelling Phase III EfficacyRobust, statistically and clinically meaningful Phase III SELVA results (95% improved) materially de-risk the core program, supporting regulatory approval, label strength, prescriber confidence and payer discussions. In rare diseases, a single pivotal trial of this magnitude sustains commercial and clinical differentiation over months.
Strong Cash Position And Low LeverageA ~ $250M cash runway and very low debt meaningfully reduce near-term liquidity and execution risk, enabling NDA completion, prelaunch investment and a scaled initial commercial build without immediate dilution. This balance-sheet strength is durable over the 2–6 month window while approvals and launches are finalized.
Regulatory Momentum And Clear NDA PathFormal FDA engagement (pre-NDA meeting, rolling review, module submission) and Breakthrough/Fast Track/Orphan designations materially shorten review uncertainty and support predictable timelines to potential approval and launch, strengthening strategic planning and commercial readiness over the next several quarters.
Bears Say
No Revenue And Large Ongoing LossesThe company remains pre-revenue with sizable recurring operating losses, meaning profitability is distant and commercial success must materialize to reverse returns. Persistent losses limit self-funding, pressure returns for investors, and make long-term success contingent on regulatory approval and successful commercialization.
Negative Operating Cash Flow / Continued Cash BurnSustained negative operating and free cash flow requires external capital to fund development and launch. Even with a sizable cash balance, planned higher 2026 spend for commercial readiness raises burn and the company remains exposed to financing risk and potential dilution if approvals or launches are delayed.
Multi‑year Timelines To Broaden MarketWhile initial approval may be reachable soon, expansion into additional indications that create the larger addressable market will take multiple years and additional pivotal studies. This lengthens the path to scale, concentrates near-term commercial risk on a single indication and delays material revenue diversification.
Palvella Therapeutics News
PVLA FAQ
What was Palvella Therapeutics, Inc.’s price range in the past 12 months?
Palvella Therapeutics, Inc. lowest stock price was $41.71 and its highest was $161.38 in the past 12 months.
What is Palvella Therapeutics, Inc.’s market cap?
Palvella Therapeutics, Inc.’s market cap is $2.23B.
When is Palvella Therapeutics, Inc.’s upcoming earnings report date?
Palvella Therapeutics, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 95 days.
How were Palvella Therapeutics, Inc.’s earnings last quarter?
Palvella Therapeutics, Inc. released its earnings results on Aug 04, 2026. The company reported -$1.52 earnings per share for the quarter, missing the consensus estimate of -$1.173 by -$0.347.
Is Palvella Therapeutics, Inc. overvalued?
According to Wall Street analysts Palvella Therapeutics, Inc.’s price is currently Undervalued.
Does Palvella Therapeutics, Inc. pay dividends?
Palvella Therapeutics, Inc. does not currently pay dividends.
What is Palvella Therapeutics, Inc.’s EPS estimate?
Palvella Therapeutics, Inc.’s EPS estimate is -1.77.
How many shares outstanding does Palvella Therapeutics, Inc. have?
Palvella Therapeutics, Inc. has 14,408,407 shares outstanding.
What happened to Palvella Therapeutics, Inc.’s price movement after its last earnings report?
Palvella Therapeutics, Inc. reported an EPS of -$1.52 in its last earnings report, missing expectations of -$1.173. Following the earnings report the stock price went up 7.963%.
Which hedge fund is a major shareholder of Palvella Therapeutics, Inc.?
Currently, no hedge funds are holding shares in PVLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palvella Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$233.82 (69.42% Upside)
$233.82 (69.42% Upside)
Blogger Sentiment
Bullish
PVLA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 52.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
257.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
243.76%
Trailing 12-Months
Company Description
Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
PVLA Company Deck
PVLA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights substantial clinical and regulatory progress—compelling Phase III SELVA results (95% improvement on primary endpoint), rolling review and first NDA module submission—supported by strong financial resources (~$251M cash) and accelerated commercial hiring (≈40 reps). Near-term risks include the need to complete the NDA, initial lack of Breakthrough for cVM (to be addressed with additional 24‑week data and qualitative evidence), increased 2026 cash spend to accelerate launch readiness, and multi-year timelines to expand indications beyond microcystic LMs. Overall, the positive clinical data, regulatory momentum, funding and clear commercial plan meaningfully outweigh the challenges and remaining execution risks.View all PVLA earnings summariesPVLA Stock 12 Month Forecast
Average Price Target
$233.82
▲(69.42% Upside)
Technical Analysis
Theravance Biopharma
―
Monopar Therapeutics Inc
―
Nurix Therapeutics
―
―
Tyra Bioscience
―
Ownership Overview
1.91% Insiders
20.71% Mutual Funds
14.51% Other Institutional Investors
51.76% Public Companies and
Individual Investors